Trials / Terminated
TerminatedNCT03516760
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- AvenCell Europe GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GEM333 | infusion of GEM333; administered intravenously and continuously over 10 days |
Timeline
- Start date
- 2018-04-11
- Primary completion
- 2022-06-14
- Completion
- 2022-06-14
- First posted
- 2018-05-04
- Last updated
- 2022-09-29
Locations
7 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03516760. Inclusion in this directory is not an endorsement.